- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05131438
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
March 23, 2023 updated by: EQRx International, Inc.
This program is intended to provide access to sugemalimab for participants with R/R ENKTL, after their disease failed to respond to prior treatment regimen(s), preceding marketing authorization by the local regulatory agency.
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Treatment IND/Protocol
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Solveig Ericson
- Phone Number: 849 617-315-2255
- Email: sericson@eqrx.com
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
Participants are eligible to receive sugemalimab as part of this EAP only if all the following criteria apply:
- Participants must be 18 to 99 years of age inclusive, at the time of signing the informed consent.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Participants who have a histologically confirmed ENKTL. Both nasal and non-nasal ENKTL are allowed.
- Participants must have R/R ENKTL that has progressed on or after asparaginase-based chemotherapy or chemoradiotherapy. (Relapse: disease progression after response to the last treatment; refractory: no response to the last treatment).
- Women of childbearing potential (WOCBP), as defined in Section 13.3 must have a negative serum pregnancy test ≤7 days before the first dose of sugemalimab. WOCBP or fertile men and their WOCBP partners must agree to use an effective contraceptive method from providing signed ICF through 6 months after the last dose of the sugemalimab.
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
Participants are not eligible to participate in the Sugemalimab ENKTL EAP if any of the following criteria apply:
- Participants with aggressive natural killer cell leukemia or ENKTL participants who have any degree of leukemic involvement.
- Participants with hemophagocytic lymphohistiocytosis.
- Subjects requiring systemic corticosteroid or any other immunosuppressive therapy. (Subjects are permitted to use topical, ocular, intra-articular, intranasal and inhaled corticosteroids [with minimal systemic absorption]; a short course [≤ 7 days] of corticosteroids for prophylaxis [e.g., hypersensitivity to contrast media] or for treatment of non-autoimmune conditions [e.g., delayed hypersensitivity caused by contacting allergens])
- Participants with underlying condition that in the treating physician's opinion would increase the risk of AEs related to sugemalimab administration or confound the assessment for its toxicity. Participants who have had prior chemotherapy, immunotherapy, biological therapy (including cancer vaccine, cytokine therapy or growth factors to treat cancer) used as a systemic treatment for cancer will require 28 days of washout period.
- Participants with active, known or suspected autoimmune disease.
- Any liver function panel analyte (LFT) value > 2.5 × upper limits of normal reference range (ULN) which includes aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and gamma-glutamyl transferase (GGT) at baseline. Bilirubin > 1.5 × ULN.
- Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection.
- Participants in the treating physician's opinion are not suitable for participating in this EAP.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 11, 2021
First Submitted That Met QC Criteria
November 11, 2021
First Posted (Actual)
November 23, 2021
Study Record Updates
Last Update Posted (Actual)
March 27, 2023
Last Update Submitted That Met QC Criteria
March 23, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EQ165-501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extranodal NK/T-cell Lymphoma
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Samsung Medical CenterCompletedExtranodal NK/T Cell LymphomaKorea, Republic of
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruitingNK-Cell Leukemia | Extranodal NK T Cell LymphomaChina
-
Ruijin HospitalUnknownNasal Type Extranodal NK/T-Cell LymphomaChina
-
Sun Yat-sen UniversityEli Lilly and Company; Hoffmann-La RocheUnknownExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Fudan UniversityTerminatedExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Beijing Tongren HospitalNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal Type
-
Jiangsu HengRui Medicine Co., Ltd.UnknownExtranodal NK/T-cell Lymphoma, Nasal TypeChina
Clinical Trials on sugemalimab
-
Sun Yat-sen UniversityRecruitingLimited Stage Small Cell Lung CancerChina
-
CStone PharmaceuticalsBlueprint Medicines CorporationCompletedHepatocellular CarcinomaChina
-
Hunan Cancer HospitalRecruitingCarcinoma, Non-Small-Cell LungChina
-
CStone PharmaceuticalsNot yet recruitingExtranodal NK/T-cell Lymphoma
-
Base Therapeutics (Shanghai) Co., Ltd.The General Hospital of Eastern Theater CommandRecruiting
-
Sichuan UniversityNot yet recruitingLung Cancer | Extensive-stage Small-cell Lung CancerChina
-
Zhejiang Cancer HospitalNot yet recruitingRadiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction ImmunochemotherapyNon-small Cell Lung Cancer Stage III